Latest News and Press Releases

FDA clearance supported by highly compelling clinical study results demonstrating 93% of subjects treated arms were “improved” or “very much improved” in appearance, following treatment utilizing...

- Third quarter revenue of $12.2M, +49% year-over-year growth- Third quarter pulse recurring revenue of $3.1M, +99% year-over-year growth- First nine months revenue of $35.0M, +60% year-over-year...

FDA clearance supported by a clinical study (n=67) and demonstrated treatment safety and efficacy utilizing SUPERB™, 97% of the treated participants in the trial showed improvement in the appearance...

–  Second quarter revenue of $12.4M, +53% year-over-year growth–  Second quarter pulse recurring revenue of $3.3M, +100% year-over-year growth–  First half revenue of $22.8M, +67% year-over-year...

• The patent protects additional feature sets of SUPERB’s ultrasound and cooling technology • New patent win is the second U.S. technology patent earned in addition to previously issued IP in China,...

First Quarter Revenue of $10.4M, +86% Year-Over-Year Growth Over 125,000 Treatments Performed Since Initial Approval; Global Market Conditions Remain Favorable and Demand Continues to Grow in the...

SAN CLEMENTE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners...

SAN CLEMENTE, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for...

“Precise” delivers the same SUPERB™ technology in a compact applicator head for more convenient and precise treatment of smaller curved areas, such as around the eyes and mouthThe modular, smaller...

 - Record Quarterly Revenue of $13.8M  - Full Year Revenue Grew 63% YoY to $35.6M  - Over 50,000 Pulse Treatments Conducted in 2022  - 2022 Recurring Revenue Up 177%, to $7.2M; Representing More...